Previous 10 | Next 10 |
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good wa...
This summer promises to be extra hot for a pair of biotech stocks that hardly anyone had heard of just a couple of years ago. BridgeBio (NASDAQ: BBIO) is launching its second drug right now, and Axsome Therapeutics (NASDAQ: AXSM) could be knee-deep into its first new drug la...
The FDA has granted Fast Track designation for BridgeBio Pharma's (BBIO) encaleret for the treatment of autosomal dominant hypocalcemia (ADH1).Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application. ADH1 is a rare, g...
PALO ALTO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today...
BridgeBio Pharma ([[BBIO]] +2.1%) through its affiliate QED Therapeutics and Helsinn Group announce that the U.S. FDA has approved TRUSELTIQ (infigratinib) under the accelerated approval program for the treatment of certain patients with cholangiocarcinoma, a cancer of the bile ducts of ...
Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement BridgeBio, through its affiliate QED (...
The following slide deck was published by BridgeBio Pharma, Inc. in conjunction with this event. For further details see: BridgeBio Pharma (BBIO) Presents At UBS Global Healthcare Virtual Conference 2021 - Slideshow
Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed from and 6 added to the universe now hol...
BridgeBio Pharma (BBIO) announces that the U.S. FDA has granted Fast Track designation to BBP-631, an investigational adeno-associated virus 5 ((AAV5)) gene therapy designed for the treatment of congenital adrenal hyperplasia ((CAH)), one of the most prevalent genetic diseases.The diseas...
PALO ALTO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today ...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...